Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Notes Payables: 2014-2022

Historic Notes Payables for ImmunityBio (IBRX) over the last 3 years, with Dec 2022 value amounting to $431.9 million.

  • ImmunityBio's Notes Payables rose 60.59% to $481.9 million in Q2 2023 from the same period last year, while for Jun 2023 it was $481.9 million, marking a year-over-year increase of 60.59%. This contributed to the annual value of $431.9 million for FY2022, which is 44.33% up from last year.
  • As of FY2022, ImmunityBio's Notes Payables stood at $431.9 million, which was up 44.33% from $299.2 million recorded in FY2021.
  • ImmunityBio's Notes Payables' 5-year high stood at $431.9 million during FY2022, with a 5-year trough of $299.2 million in FY2021.
  • Over the past 2 years, ImmunityBio's median Notes Payables value was $365.6 million (recorded in 2021), while the average stood at $365.6 million.
  • Data for ImmunityBio's Notes Payables shows a peak YoY spiked of 44.33% (in 2022) over the last 5 years.
  • ImmunityBio's Notes Payables (Yearly) stood at $299.2 million in 2021, then spiked by 44.33% to $431.9 million in 2022.